Press Center

• Nephros Announces Two Million Dollar Private Placement
• May 16, 2019
• Nephros Announces $2 Million Private Placement SOUTH ORANGE, NJ, May 16, 2019 – Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage company that develops and sells high performance water purification products to the medical device and commercial markets, today announced that it has completed a private placement in which it sold approximately 4.4 million shares … Continue reading Nephros Announces Two Million Dollar Private Placement →
• Read More »

• Nephros Reports First Quarter Financial Results
• May 08, 2019
• Revenues up 80% over Q1 2018 Driven by Hospital Footprint Expansion Reiterates 2019 Guidance for Revenue Growth of 50% to 65% SOUTH ORANGE, NJ, May 8, 2019 – Nephros, Inc. (OTCQB:NEPH), a commercial stage company that develops and sells high performance water purification products to the medical device and commercial markets, today announced financial results … Continue reading Nephros Reports First Quarter Financial Results →
• Read More »

• Nephros Appoints Tom Gwydir to its Board of Directors
• May 01, 2019
• SOUTH ORANGE, NJ, May 1, 2019 – Nephros, Inc. (OTCQB: NEPH), a commercial stage company that develops and sells high-performance water purification products to the medical device and commercial markets, today announced the appointment of Tom Gwydir to its Board of Directors.
• Read More »

• Nephros to Report First Quarter 2019 Financial Results on May 8, 2019
• May 01, 2019
• SOUTH ORANGE, NJ, May 1, 2019 – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced that it will issue its first quarter 2019 financial results on Wednesday, May 8, 2019. The company will also host a conference call at 4:30 PM ET, during which management will discuss the company's financial results and provide a general business overview.
• Read More »

• Nephros To Present at Taglich Brothers 16th Annual Investment Conference on April 30, 2019 in New York City
• April 24, 2019
• SOUTH ORANGE, NJ, April 24, 2019 – Nephros, Inc. (OTCQB:NEPH), a commercial stage company that develops and sells high performance liquid purification filters for both medical device and commercial markets, today announced that Daron Evans, CEO and Andy Astor, CFO will be presenting at the Taglich Brothers 16th Annual Investment Conference on Tuesday, April 30th at 9:30 AM ET in New York City.
• Read More »

Download PDF »

• Nephros Announces Preliminary Financial Results for First Quarter 2019 Anticipates $1.7 Million Revenue; Year-over-Year Growth Exceeds 75%  
• April 08, 2019
• SOUTH ORANGE, NJ, April 8, 2019 – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device and commercial products company that develops and sells high performance water purification products, today announced preliminary financial results for the quarter ended March 31, 2019.
• Read More »

• Nephros To Present at the Spring Investor Summit on April 1st in New York City
• March 29, 2019
• (OTCQB:NEPH), a commercial stage company that develops and sells high performance liquid purification filters for both medical device and commercial markets, today announced that Andy Astor, CFO will be presenting at this year's Spring Investor Summit on April 1st at 11:30 AM ET in New York City.
• Read More »

• Nephros Reports 2018 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Annual Product Revenues Up 54%
• March 12, 2019
• SOUTH ORANGE, NJ, March 12, 2019 – Nephros, Inc. (OTCQB:NEPH), a commercial stage company that develops and sells high-performance liquid purification filters for both medical device and commercial markets, today announced financial results for the three months and full year ended December 31, 2018.
• Read More »

• Nephros to Present at the 2019 LD Micro Virtual Conference
• March 07, 2019
• LOS ANGELES, CA / ACCESSWIRE / March 7, 2019 / Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced that it will be presenting at the second annual LD Micro Virtual Conference on Tuesday, March 12th at 12:20 PM Eastern Time. Daron Evans, CEO of Nephros will be giving the presentation. He and Andy Astor, COO and CFO, will also be answering questions from investors. You can access the webcast presentation at the following link: https://bit.ly/2EJIr1s
• Read More »

• Nephros to Report Fourth Quarter and Year-End 2018 Financial Results on March 12, 2019
• March 06, 2019
• SOUTH ORANGE, NJ, March 6, 2019 – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced that it will issue its fourth quarter and year-end 2018 financial results on Tuesday, March 12, 2019. The company will also host a conference call at 10:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.
• Read More »

• Nephros Appoints Alisa Lask to its Board of Directors
• February 11, 2019
• SOUTH ORANGE, NJ, February 11, 2018 – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced the appointment of Alisa Lask to its Board of Directors. Additionally, Moshe Pinto has resigned from the Nephros Board of Directors to focus his activities on the Board of Directors of Specialty Renal Products, Inc., Nephros’ majority-owned subsidiary developing a second generation hemodiafiltration device.
• Read More »

• Nephros Announces Preliminary Financial Results for Fiscal Year 2018
• January 09, 2019
• SOUTH ORANGE, NJ, January 9, 2018 – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced preliminary financial results for fiscal year 2018.
• Read More »

• Nephros Announces Acquisition of Biocon
• January 02, 2019
• Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, known as ultrafilters. Nephros ultrafilters are primarily used in hospitals and medical clinics for added protection in retaining bacteria (e.g., Legionella, Pseudomonas), viruses, and endotoxins from water, providing barriers that assist in improving infection control in showers, sinks, and ice machines. Additionally, Nephros ultrafilters are used by dialysis centers for assisting in the added removal of biological contaminants from the water and bicarbonate concentrate supplied to hemodialysis machines and the patients.
• Read More »

• Nephros to Present at the 11th Annual LD Micro Main Event
• December 03, 2018
• SOUTH ORANGE, NJ, December 3, 2018 – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced that its executive management will present at the 11th Annual LD Micro Main Event at the Luxe Sunset Hotel, Bel-Air, California on Tuesday December 4, at 9:30 AM PT.
• Read More »

• Nephros Reports Third Quarter 2018 Financial Results
• November 08, 2018
• SOUTH ORANGE, NJ, November 8, 2018 – Nephros, Inc. (OTCQB: NEPH) (“Nephros”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced financial results for the three months ended September 30, 2018.
• Read More »

• Nephros to Report Third Quarter 2018 Financial Results on November 8th, 2018
• November 01, 2018
• SOUTH ORANGE, NJ, November 1, 2018 – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced that it will issue its third quarter 2018 financial results on Thursday, November 8, 2018.
• Read More »

• Nephros Announces Preliminary Financial Results for Third Quarter 2018
• October 01, 2018
• SOUTH ORANGE, NJ, Oct. 01, 2018 -- Nephros, Inc. (NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced preliminary financial results for the third quarter of 2018.
• Read More »

• Specialty Renal Products Announces $3 Million Series A Financing
• September 06, 2018
• SOUTH ORANGE, NJ, September 6, 2018 – Specialty Renal Products, Inc. (SRP), a private medical device company focused on the development of products for patients with renal disease, including a hemodiafiltration (HDF) system for the treatment of patients with End Stage Renal Disease (ESRD), and a subsidiary of Nephros, Inc. (OTCQB: NEPH), announced today that is has closed a $3 million Series A financing.
• Read More »

• Nephros Subsidiary Specialty Renal Products and HemoCleanse Announce License Agreement for Dialysate Filtration System
• August 14, 2018
• SOUTH ORANGE, NJ, August 14, 2018 – Specialty Renal Products, Inc. (SRP), a subsidiary of Nephros, Inc. (OTCQB:NEPH), a medical device company that develops and sells a hemodiafiltration system for the treatment of patients with End Stage Renal Disease (ESRD), and HemoCleanse Technologies, LLC, (HCT) a medical device company focused on the development of sorbent products to improve outcomes for patients on hemodialysis (HD), announced today that they have entered into an exclusive agreement to develop and commercialize a dialysate regeneration and filtration system.
• Read More »

• Nephros Appoints Oliver Spandow to its Board of Directors
• August 13, 2018
• SOUTH ORANGE, NJ, August 13, 2018 -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters announced today the appointment of Oliver Spandow to its Board of Directors.
• Read More »

• Nephros Reports Second Quarter 2018 Financial Results
• August 08, 2018
• SOUTH ORANGE, NJ, August 8, 2018 – Nephros, Inc. (OTCQB: NEPH) (“Nephros”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced financial results for the three months ended June 30, 2018.
• Read More »

• Nephros Schedules Second Quarter Financial Results Conference Call
• August 03, 2018
• August 3, 2018 – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (HDF) system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced that it will issue its second quarter 2018 financial results on Wednesday, August 8, 2018. The company will also host a conference call at 4:30 PM EDT that afternoon, during which management will discuss the company's financial results and provide a general business overview.
• Read More »

• Nephros Announces Preliminary Financial Results for Second Quarter 2018
• July 09, 2018
• SOUTH ORANGE, NJ, July 9, 2018 /PR Newswire-FirstCall/ – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (HDF) system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced preliminary financial results for the second quarter of 2018.
• Read More »

• Nephros to Present at 8th Annual LD Micro Invitational
• June 04, 2018
• SOUTH ORANGE, NJ, June 4, 2018 /PR Newswire-FirstCall/ – Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (HDF) system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced that its Chief Financial Officer, Andy Astor, will present at the 8th Annual LD Micro Invitational Investor Conference at the Luxe Sunset Hotel, Bel-Air, California on Tuesday, June 5 at 9:30am PDT.
• Read More »

• Medical Device Company Nephros, Inc. Credits State’s NOL Program with Fueling Growth
• May 10, 2018
• TRENTON, N.J. (May 10, 2018) – With support from the New Jersey Economic Development Authority (EDA), medical device maker Nephros, Inc. has developed and commercialized water-filtration systems designed to decrease the incidence of infectious diseases in hospitals and dialysis clinics. More than 500 facilities in the United States currently use the South Orange-based company’s innovative technology.
• Read More »

• Nephros Reports First Quarter 2018 Financial Results
• May 09, 2018
• SOUTH ORANGE, NJ, May 9, 2018 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB: NEPH) (“Nephros”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced financial results for the three months ended March 31, 2018.
• Read More »

• Nephros Announces Preliminary Financial Results for First Quarter 2018
• April 16, 2018
• SOUTH ORANGE, NJ, April 16, 2018 /PR Newswire-FirstCall/ – Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (HDF) system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced preliminary financial results for the first quarter of 2018.
• Read More »

• Nephros Announces $2.9 Million Private Placement
• April 11, 2018
• SOUTH ORANGE, NJ, April 11, 2018 /PR Newswire-FirstCall/ – Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (HDF) system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced that it has completed a private placement in which it sold approximately 6.5 million shares of common stock at a purchase price of $0.45 per share, resulting in total gross proceeds to the company of over $2.9 million.
• Read More »

• Nephros Reports 2017 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
• February 26, 2018
• SOUTH ORANGE, NJ, February 26, 2018 /PR Newswire-FirstCall/ – Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (HDF) system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced financial results for the three months and full year ended December 31, 2017.
• Read More »

• Nephros to Present at NobleCon14
• January 23, 2018
• SOUTH ORANGE, NJ, January 23, 2018 /PR Newswire-FirstCall/ - Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (HDF) system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced that its Chief Financial Officer, Andy Astor, will present at NobleCon14 - Noble Capital Markets' Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Tuesday, January 30 at 12:00 Noon EST.
• Read More »

• Nephros Announces Preliminary Financial Results for Fourth Quarter 2017
• January 04, 2018
• SOUTH ORANGE, NJ, January 4, 2018 /PR Newswire-FirstCall/ – Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (HDF) system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced preliminary financial results for the fourth quarter of 2017.
• Read More »

• Nephros Receives $1.8 Million in Cash from Sale of Tax Credits
• December 13, 2017
• SOUTH ORANGE, NJ, December 13, 2017 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB: NEPH) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), announced today the receipt of $1.788 million in cash from the sale of $1.901 million in tax credits.
• Read More »

• Nephros CFO to Present at the 10th Annual LD Micro Main Event
• December 04, 2017
• LOS ANGELES, CA / ACCESSWIRE / December 4, 2017 / Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), announced today that Andy Astor, Chief Financial Officer will present at the 10th annual LD Micro Main Event on Wednesday, December 6, at 9:30AM PST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
• Read More »

• Nephros Reports Third Quarter 2017 Financial Results
• November 09, 2017
• RIVER EDGE, NJ, November 9, 2017 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB: NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced financial results for the three months ended September 30, 2017.
• Read More »

• Nephros Announces Approval of $1.9 Million in NJEDA NOL Program Tax Credits
• November 06, 2017
• RIVER EDGE, NJ, November 6, 2017 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB: NEPH) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), announced today the receipt of $1.9 million in tax credit certificates from New Jersey Economic Development Authority (NJEDA), which are expected be sold later this quarter for over $1.75 million in net proceeds.
• Read More »

• Nephros Provides Corporate Update and Announces Preliminary Third Quarter 2017 Revenue
• October 16, 2017
• RIVER EDGE, NJ, October 16, 2017 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), is providing a general update on the Company’s activities and guidance for the third quarter of 2017.
• Read More »

• Nephros Shareholder Letter – 9/27/2017
• September 27, 2017
• This is an exciting time for Nephros. Demand for our products is increasing, revenue and growth rates are expanding, and we anticipate continued progress.
• Read More »

• Nephros Reports Second Quarter Financial Results and Receives NJEDA Approval for Approximately $1.5 million in Funding from Sale of Tax Credits
• August 08, 2017
• RIVER EDGE, NJ, August 8, 2017 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), announced financial results for the three months ended June 30, 2017. The Company also announced that it has received approval to sell a percentage of its net operating losses (“NOLs”) and research and development tax credits under The Technology Business Tax Certificate Transfer Program by the New Jersey Economic Development Authority (“NJEDA”).
• Read More »

• Nephros to Present at Marcum 2017 MicroCap Conference
• June 09, 2017
• RIVER EDGE, NJ, June 9, 2017 -- Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced that Andrew Astor, Chief Financial Officer, will present at the Marcum MicroCap Conference on Thursday June 15, 2017 at 4:00pm ET. The conference is being held at the Grand Hyatt Hotel, New York City. Management will also be available to meet with investors during the conference.
• Read More »

• Nephros Reports 2017 First Quarter Financial Results and Provides Corporate Update
• May 09, 2017
• RIVER EDGE, NJ, May 9, 2017 /Marketwired/ -- Nephros, Inc. (OTCQB: NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today financial results for the three months ended March 31, 2017.
• Read More »

• Nephros Announces Partnership with WorldWater & Solar Technologies
• April 24, 2017
• RIVER EDGE, NJ, April 24, 2017 /Issuer Direct / Nephros, Inc. (OTCQB:NEPH), (the “Company”) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, and WorldWater & Solar Technologies, Inc., a leader in integrated solar platform technology that uses sunshine to drive motors and pumps in large-scale irrigation and municipal water delivery systems, jointly announced today that they have signed a partnership agreement to incorporate Nephros ultrafilters into their solar powered drinking water systems.
• Read More »

• Nephros Reports 2016 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
• March 20, 2017
• RIVER EDGE, NJ, March 20, 2017 /Marketwired/ -- Nephros, Inc. (OTCQB:NEPH), (the “Company”) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today financial results for the three months and full year ended December 31, 2016.
• Read More »

• Nephros Announces $1.2 Million Private Placement
• March 17, 2017
• RIVER EDGE, NJ--(Marketwired - Mar 17, 2017) - Nephros, Inc. ( OTCQB : NEPH ) (the "Company"), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced that it has entered into definitive agreements to sell 4,059,994 shares of common stock at a purchase price of $0.30 per share to institutional and accredited investors. In connection with the offering, the investors will also receive warrants to purchase up to an aggregate of 4,059,994 shares of common stock with an exercise price of $0.30 per share and are exercisable for a five year term. The transaction is expected to close on or about March 22, 2017, subject to satisfying customary closing conditions.
• Read More »

• Nephros Receives FDA 510(k) Clearance of EndoPur Endotoxin 10” Filter
• March 06, 2017
• RIVER EDGE, NJ, March 6, 2017 /MarketWired/ -- Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its EndoPur Endotoxin 10” Filter.
• Read More »

• Nephros Announces Appointment of Andrew Astor as Chief Financial Officer
• February 14, 2017
• RIVER EDGE, NJ, February 14, 2017 /Market Wire/ -- Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), announced today that it had hired Andrew Astor as Chief Financial Officer.
• Read More »

• Nephros Provides Corporate Update and Fourth Quarter 2016 Revenue Guidance
• January 24, 2017
• RIVER EDGE, NJ, January 24, 2017 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), is providing a general update on the Company’s activities and guidance for the fourth quarter of 2016.
• Read More »

• Nephros Receives FDA 510(k) Clearance of HydraGuard 10” UltraFilter
• December 27, 2016
• RIVER EDGE, NJ, December 27, 2016 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its HydraGuard 10” UltraFilter.
• Read More »

• Nephros Provides Corporate Update and Third Quarter 2016 Revenue Guidance
• October 11, 2016
• RIVER EDGE, NJ, October 11, 2016 /Issuer Direct/ -- Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), is providing a general update on the Company’s activities and guidance for the third quarter of 2016. The Company is also announcing a new HDF cost-effectiveness analysis published in a peer-reviewed journal.
• Read More »

• Nephros Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference
• August 29, 2016
• RIVER EDGE, NJ, August 29, 2016 /Issuer Direct -- Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (“HD”) machine for the treatment of patients with end stage renal disease (“ESRD”), today announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City.
• Read More »

• Nephros Announces Agreement to Initiate HDF Treatment at Vanderbilt Dialysis Clinic
• August 25, 2016
• RIVER EDGE, NJ, August 25, 2016 /Issuer Direct/ -- Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), announced today that it has signed an agreement to enable a Vanderbilt Dialysis Clinic to offer hemodiafiltration (HDF) to patients
• Read More »

• Nephros Reports Second Quarter 2016 Financial Results
• August 08, 2016
• RIVER EDGE, NJ, August 08, 2016 -- Nephros, Inc. (OTCQB: NEPH), (the “Company”) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, today announced financial results for the three months ended June 30, 2016.
• Read More »

• Nephros Announces Closing of $1.2 Million Note and Warrant Offering
• June 09, 2016
• RIVER EDGE, NJ, June 9, 2016 /Issuer’s Direct/ -- Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has completed a private placement of unsecured promissory notes and warrants to purchase the Company’s common stock resulting in total gross proceeds to the Company of approximately $1.2 million.
• Read More »

• Nephros, Inc. Announces Distribution Agreement with CS Medical, LLC
• May 23, 2016
• RIVER EDGE, NJ, May 23 , 2016 /Issuer Direct / -- Nephros, Inc. (OTCQB:NEPH), (the “Company”) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today that it has signed a distribution agreement with CS Medical, LLC, a leader in developing, manufacturing, and marketing medical devices designed to provide high-level disinfection of ultrasound Trans-Esophageal Echocardiogram (“TEE”) probes.
• Read More »

• Nephros Reports First Quarter 2016 Financial Results
• May 11, 2016
• RIVER EDGE, NJ, May 11, 2016 -- Nephros, Inc. (OTCQB: NEPH), (the “Company”) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today financial results for the three months ended March 31, 2016.
• Read More »

• Nephros Announces Submission of Special 510(k) Application to the FDA for the EndoPurTM Ultrafilter
• April 21, 2016
• RIVER EDGE, NJ, April 21, 2016 /Issuer Direct / -- Nephros, Inc. (OTCQB:NEPH), (the “Company”) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has submitted a Special 510(k) application to the U.S. Food and Drug Administration (FDA) for its EndoPurTM ultrafilter designed to provide hemodialysis quality water.
• Read More »

• Nephros Receives FDA 510(k) Clearance of S100 Point of Use Filter
• April 14, 2016
• RIVER EDGE, NJ, April 14, 2016-- Nephros, Inc. (OTCQB:NEPH), (the “Company”) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its S100 Point of Use filter designed to filter Environmental Protection Agency (“EPA”) quality drinking water to retain waterborne bacteria to assist in infection control.
• Read More »

• Nephros Reports 2015 Fourth Quarter and Full Year Financial Results; Provides 2016 Guidance and Potential Upcoming Milestones
• March 30, 2016
• RIVER EDGE, NJ, March 30, 2016 -- Nephros, Inc. (OTCQB: NEPH), (the “Company”) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today financial results for the three months and full year ended December 31, 2015.
• Read More »

• Nephros Launches SSUmini and Provides S100 Update
• March 16, 2016
• RIVER EDGE, NJ, March 16, 2016 /Businesswire/ -- Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announces the release of the SSUmini, a smaller version of its SSU-D medical device.
• Read More »

• Nephros Reports Preliminary 2015 Revenue and Provides Update
• February 01, 2016
• RIVER EDGE, NJ, February 1, 2016 /Businesswire/ -- Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, reports preliminary top-line revenue for the fiscal year 2015 and provides business update.
• Read More »

• Nephros Announces  Publication of Observational Trial of DSU-D in a Hospital-Based Dialysis Facility
• January 18, 2016
• RIVER EDGE, NJ, January 18, 2016 /Businesswire / -- Nephros, Inc. (OTCQB:NEPH),(the “Company”) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with hemodialysis machines for the treatment of ESRD patients, announced today that data about Nephros’ DSU-D ultrafilter was published online in Case Reports in Nephrology and Dialysis.
• Read More »

• Nephros Announces Retirement of Chairman
• December 30, 2015
• RIVER EDGE, NJ, December 30, 2015 /Businesswire / -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today that the company’s Chairman, Lawrence Centella, has decided to retire from the Nephros Board of Directors, effective December 31, 2015.
• Read More »

• Nephros, Inc. Completes Warrant Exercise Offer
• December 21, 2015
• River Edge, NJ, December 21, 2015/Businesswire/ -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, today announced that it had received gross proceeds of approximately $688,000 in connection with its offer to holders of certain warrants of the opportunity to exercise their warrants at a temporarily reduced cash exercise price. Nephros intends to use the proceeds to further develop its products, for working capital, and for general corporate purposes.
• Read More »

• Nephros, Inc. Announces Offer to Exercise 2011 Warrants
• November 20, 2015
• River Edge, NJ, November 20, 2015 /Businesswire/ -- Nephros, Inc. (OTCQB: NEPH), acommercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, today announced the commencement of an offer to holders of certain warrants the opportunity to exercise their warrants at a temporarily reduced cash exercise price of $0.20 per share of common stock.
• Read More »

• Nephros Announces Strategic Collaboration with Biocon 1, LLC
• November 18, 2015
• RIVER EDGE, NJ, November 18, 2015 /Businesswire/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today that it has initiated a strategic collaboration with Biocon 1, LLC, a commercial water purification company that markets the AETHER® Water Systems technology, expanding the use of Nephros technology into the food service industry and the use of Biocon technology into the medical industry
• Read More »

• Nephros Reports 2015 Third Quarter Financial Results
• November 10, 2015
• RIVER EDGE, NJ, November 10, 2015 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (HDF) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today financial results for the three and nine months ended September 30, 2015.
• Read More »

• Nephros Announces FDA 510(k) Submission of S100 Ultrafilter
• October 27, 2015
• RIVER EDGE, NJ, October 27, 2015 /Businesswire/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today that it has submitted to the U.S. Food and Drug
• Read More »

• Nephros Announces Upcoming Poster Presentation at the American Society of Nephrology’s Kidney Week 2015
• October 22, 2015
• Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today that data about Nephros’ DSU-D ultrafilter will be presented in a poster at the American Society of Nephrology's Kidney Week 2015 in San Diego, California.
• Read More »

• Nephros Announces Funding from Warrant Exercise by Wexford Capital and Plan to Temporarily Reduce Exercise Price for All Outstanding Warrants
• September 30, 2015
• RIVER EDGE, NJ, September 30, 2015 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today that it has entered into a Warrant Amendment and Exercise Agreement with Lambda Investors LLC (“Lambda”), an affiliate of Wexford Capital LP (“Wexford”), and its plans to initiate a tender offer to temporarily reduce the exercise price for all remaining outstanding warrants by 50% of the stated exercise price of each respective warrant.
• Read More »

Download PDF »

• Nephros to Present at Upcoming Investor Conferences
• September 29, 2015
• RIVER EDGE, NJ, September 29, 2015 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today that Mr. Daron Evans, Chief Executive Officer, will present at two upcoming investor conferences:
• Read More »

• Nephros Introduces the “Nephros Challenge” Campaign
• September 21, 2015
• RIVER EDGE, NJ, September 21, 2015 /Businesswire/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today that it has launched the “Nephros Challenge” campaign, a program designed to encourage dialysis clinics to evaluate the performance improvement potential from using Nephros ultrafilters to assist in providing dialysis quality water or bicarbonate concentrate.
• Read More »

• Nephros Appoints Moshe Pinto to its Board of Directors
• August 17, 2015
• RIVER EDGE, NJ, August 17, 2015 /Businesswire/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today the appointment of Moshe Pinto, to its Board of Directors.
• Read More »

• Nephros Reports 2015 Second Quarter Financial Results
• August 10, 2015
• RIVER EDGE, NJ, August 10, 2015 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (HDF) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today financial results for the three months ended June 30, 2015.
• Read More »

• Nephros, Inc. Enters Into Purchase Agreement with Lincoln Park Capital Fund, LLC
• July 27, 2015
• RIVER EDGE, N.J., July 27, 2015 - Nephros, Inc. (OTCBB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF") system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor. Under the terms of the purchase agreement, over a 36-month term, Nephros will have the right and the sole discretion to sell to LPC up to $10 million worth of shares of Nephros common stock in amounts as set forth in the agreement. Nephros will control the timing and amount of any future investment and LPC will be obligated to make purchases in accordance with the agreement.
• Read More »

• Nephros Announces the Closing of its $1.2M Private Placement
• May 19, 2015
• RIVER EDGE, NJ, May 19, 2015 /Businesswire/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has closed its previously announced private placement offering for gross proceeds of approximately $1.23 million, wherein the Company issued approximately 1.83 million shares of the Company's common stock, and 5 year warrants to purchase approximately 0.92 million shares of common stock at $0.85 per share.
• Read More »

• Nephros Reports 2015 First Quarter Financial Results
• May 14, 2015
• RIVER EDGE, NJ, May 15, 2015 /Businesswire/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (HDF) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today financial results for the three months ended March 31, 2015.
• Read More »

• Nephros Announces $1.2M Private Placement
• May 12, 2015
• RIVER EDGE, NJ, May 12, 2015 /Businesswire/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it had signed definitive agreements for the sale of approximately $1.2 million of the Company's common stock at a price of $0.67 per share, or approximately 1.8 million shares.
• Read More »

• Nephros Appoints Malcolm Persen to Board of Directors
• May 08, 2015
• RIVER EDGE, NJ, May 8, 2015 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today the appointment of Malcolm Persen, to its Board of Directors and as the Chair of the Audit Committee.
• Read More »

• Nephros Licenses HydraGuard Military Filter to CamelBak®
• May 06, 2015
• RIVER EDGE, NJ, May 6, 2015 /Businesswire/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today that the Company has exclusively licensed its HydraGuard military filter to CamelBak®.
• Read More »

• Nephros to Present at Upcoming Investor Conferences
• April 22, 2015
• RIVER EDGE, NJ, April 22, 2015 /Businesswire/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today that Mr. Daron Evans, Chief Executive Officer, will present at two upcoming investor conferences in New York.
• Read More »

• Nephros Announces Successful Completion of $3 million Rights Offering
• December 18, 2014
• RIVER EDGE, NJ, December 18, 2014 -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today the successful completion of its rights offering.
• Read More »

• Nephros Receives 510(k) Clearance for DSU-H and SSU-H Ultrafilters
• October 28, 2014
• RIVER EDGE, NJ, October 28, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, today announced that the Company has received 510(k) clearance from the Food and Drug Administration (“FDA”) to market its DSU-H and SSU-H Ultrafilters for use in the hospital setting.
• Read More »

• Nephros Completes Bridge Financing
• September 03, 2014
• RIVER EDGE, NJ, September 3, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, today announced that the company has entered into a bridge loan and security agreement with Lambda Investors LLC, an affiliate of Wexford Capital LP and the company’s largest shareholder.
• Read More »

• Nephros Reports Second Quarter 2014 Financial Results
• August 14, 2015
• RIVER EDGE, NJ, August 14, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today financial results for the three and six months ended June 30, 2014.
• Read More »

• Nephros Announces FDA 510(k) Submission of DSU-H and SSU-H Ultrafilters to be used to filter EPA quality drinking water to remove microbiological contaminants and waterborne pathogens
• June 30, 2014
• RIVER EDGE, NJ, June 30, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today that it has submitted to the U.S. Food and Drug Administration (FDA), for 510(k) clearance, the DSU-H and SSU-H Ultrafilters to filter Environmental Protection Agency (EPA) quality drinking water to remove microbiological contaminants and waterborne pathogens.
• Read More »

• Nephros Appoints Matthew S. Rosenberg to Board of Directors
• May 19, 2014
• RIVER EDGE, NJ, May 19, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today the appointment of Matthew S. Rosenberg, M.D., to its Board of Directors.
• Read More »

• Nephros to Present at the Third Annual Marcum MicroCap Conference
• May 14, 2014
• RIVER EDGE, NJ, May 14, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today that John C. Houghton, President and Chief Executive Officer, will present at the Third Annual Marcum MicroCap Conference in New York on Thursday, May 29, 2014 at 3:30 p.m. EDT.
• Read More »

• Nephros Reports First Quarter 2014 Financial Results
• May 14, 2014
• RIVER EDGE, NJ, May 14, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today financial results for the three months ended March 31, 2014.
• Read More »

• Nephros Announces First Commercial Placement of its FDA-Cleared On-line Mid-dilution Hemodiafiltration System in the United States
• May 13, 2014
• RIVER EDGE, NJ, May 13, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today the first commercial use of its hemodiafiltration (“HDF”) system in the United States.
• Read More »

• Nephros Reports 2013 Fourth Quarter and Full Year Financial Results
• March 28, 2014
• RIVER EDGE, NJ, March 28, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today financial results for the three months and full year ended December 31, 2013.
• Read More »

• Nephros Announces Completion of Rights Offering
• March 24, 2014
• RIVER EDGE, NJ, March 24, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today the successful completion of its rights offering.
• Read More »

• Nephros and Mar Cor Purification Announce Distribution Agreement
• March 11, 2014
• RIVER EDGE, NJ, March 11, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and Mar Cor Purification, a wholly owned subsidiary of Cantel Medical Corp., announced today that the companies have signed a non-exclusive distributor agreement to distribute Nephros’s dialysis ultrafilters to U.S. and Canadian dialysis clinics.
• Read More »

• Nephros Provides Corporate Update
• March 11, 2014
• RIVER EDGE, NJ, March 11, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and a Hemodiafiltration system for the treatment of chronic renal failure patients today provided an update on its operations and strategy.
• Read More »

• Nephros Announces Rights Offering
• February 12, 2014
• RIVER EDGE, NJ - /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today that it has commenced its previously disclosed rights offering. On February 12, 2014, the Company will distribute to holders of its common stock and/or warrants one non-transferable subscription right for each share of common stock, and each share of common stock underlying a warrant, held as of January 30, 2014. The rights offering will expire at 5:00 p.m., Eastern Time, on March 14, 2014, if not extended by the Company in its sole discretion.
• Read More »

• Nephros Reports Second Quarter 2013 Financial Results
• August 13, 2013
• RIVER EDGE, NJ, August 13, 2013 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced financial results for the three and six months ended June 30, 2013.
• Read More »

• Nephros Reports Third Quarter 2013 Financial Results and Completes Bridge Financing
• November 14, 2013
• RIVER EDGE, NJ, November 14, 2013 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today financial results for the three and nine months ended September 30th 2013 and that the company entered into a bridge loan and security agreement with Lambda Investors LLC, an affiliate of Wexford Capital LP and the company’s largest shareholder.
• Read More »

• Nephros Appoints Daron Evans to Board of Directors
• November 29, 2013
• RIVER EDGE, NJ, November 29, 2013 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today the appointment of Daron Evans to its Board of Directors. Mr. Evans replaces James S. Scibetta who will be leaving the Board effective December 31, 2013. Mr. Evans was also named a member of the Audit Committee.
• Read More »

• Nephros Announces Completion of Rights Offering
• May 23, 2013
• RIVER EDGE, NJ, May 23, 2013 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today the successful completion of its rights offering. In addition, the concurrent temporary reduction in exercise price for the company’s March 2011 warrants expired on May 17, 2013.
• Read More »

• Nephros Reports First Quarter 2013 Financial Results
• May 08, 2013
• RIVER EDGE, NJ, May 8, 2013 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today financial results for the three months ended March 31, 2013.
• Read More »

• Nephros Reports 2012 Fourth Quarter and Full Year Financial Results
• March 04, 2013
• RIVER EDGE, NJ, March 4, 2013 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today financial results for the three months and full year ended December 31, 2012.
• Read More »

• Nephros and Chem-Aqua Announce Distribution Agreement
• February 04, 2013
• RIVER EDGE, NJ, February 4, 2013 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH) and Chem-Aqua, Inc., a wholly owned water treatment subsidiary of NCH Corporation, announced today that the companies have signed a non-exclusive distributor agreement for Chem-Aqua to distribute Nephros’s innovative ultrafilters in North America. Chem-Aqua is now beginning launch efforts, including scheduling training sessions and promoting ultrafilters to the hospital market.
• Read More »

• Nephros Completes Bridge Financing
• February 04, 2013
• RIVER EDGE, NJ, February 4, 2013 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced that the company has entered into a bridge loan and security agreement with Lambda Investors LLC, an affiliate of Wexford Capital LP and the company’s largest shareholder.
• Read More »

• Nephros Receives €600,000 Payment from Bellco S.r.l.
• January 15, 2013
• RIVER EDGE, NJ, January 15, 2013 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced that on January 15, 2013, Nephros received the scheduled payment of €600,000 from Bellco S.r.l. under the previously announced license agreement.
• Read More »

• Nephros Announces Strategic License and Supply Agreement with Medica S.p.A for Ultrafiltration Products
• April 23, 2012
• RIVER EDGE, NJ - April 23, 2012 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and advanced water purification solutions, today announced that the company has entered into a strategic license and supply agreement with Medica S.p.A. That agreement, which is effective April 23, 2012, grants Nephros exclusive global rights, with specific exceptions, to market products based on Medica’s proprietary Medisulfone ultrafiltration technology.
• Read More »

• Nephros Reports Third Quarter 2012 Financial Results
• November 08, 2012
• RIVER EDGE, NJ, November 8, 2012 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today financial results for the three and nine months ended September 30, 2012.
• Read More »

• Nephros Reports Second Quarter 2012 Financial Results
• August 14, 2012
• RIVER EDGE, NJ, August 14, 2012 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH), a global medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, announced today financial results for the three and six months ended June 30, 2012.
• Read More »

• Nephros Announces Expansion of U.S. Sales Team
• July 24, 2012
• RIVER EDGE, NJ, July 24, 2012 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH), a global medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, announced today the expansion of its U.S. Sales Team
• Read More »

• Nephros Reports First Quarter 2012 Financial Results
• May 15, 2012
• RIVER EDGE, NJ, May 15, 2012 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH), a global medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, announced today financial results for the three months ended March 31, 2012.
• Read More »

• Nephros Appoints John C. Houghton as President and Chief Executive Officer
• April 23, 2012
• RIVER EDGE, NJ - April 23, 2012 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that effective April 20, 2012, John C. Houghton has been appointed as President and Chief Executive Officer. In addition, Mr. Houghton is expected to be appointed to the board of directors of Nephros. Effective upon Mr. Houghton’s appointment, Dr. Paul Mieyal stepped down as acting CEO of Nephros and will remain as a member of the board of directors of Nephros.
• Read More »

• Nephros Hires Director of U.S. Sales
• March 14, 2012
• RIVER EDGE, NJ - March 14, 2012 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that the company has hired Shane Sullivan as Director of U.S. Sales.
• Read More »

• Nephros, Inc. Announces Date of its 2012 Annual Meeting of Stockholders
• February 10, 2012
• RIVER EDGE, NJ - February 10, 2012 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that it will hold its 2012 Annual Meeting of Stockholders (the “Annual Meeting”) at the Crowne Plaza Hotel, 401 South Van Brunt Street, Englewood, New Jersey, on April, 23, 2012 at 10:00 a.m., Eastern Time.
• Read More »

• Nephros Receives €750,000 Payment from Bellco S.r.l.
• January 17, 2012
• RIVER EDGE, N.J., January 17, 2012 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board:NEPH.OB - News), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that on January 16, 2012, Nephros received a payment of €750,000 from Bellco S.r.l. under the previously announced license agreement.
• Read More »